Clinical trials: Lifestyle-Related Condition
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Training Attentional Awareness and Control in ADHD
The purpose of this study is to evaluate the effects of different types of cognitive training on attention in adults with Attention Deficit Hyperactivity Disorder (ADHD) using mobile software on personal mobile devices.
- Trial name
- SAC-I (NCT02489279)
- Testing
- Sustained Attention Control (SAC) Method, Scrabble
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Think Now Incorporated
ADHD, PMS
Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
- Trial name
- NCT03676725
- Testing
- Lidocaine gel
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- PhenoSolve, LLC
ADHD, Sleep Disturbance
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant…
- Conditions
- ADHD, Sleep Disturbance, Brain Fog
- Trial name
- NCT07380412
- Testing
- Stasis Daytime and Nighttime
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Outliers, Inc.
Attention Deficit and Hyperactivity Disorder
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01174355
- Testing
- ND0801
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- NeuroDerm Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England
The main aim of the study is to learn about the demographic and clinical characteristics, healthcare resources utilization (HCRU) and costs associated with before and after ADHD diagnosis in England.
- Trial name
- NCT05137704
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 2,236 people
- Sponsor
- Takeda
Impulsive Aggression Comorbid With ADHD
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers
- Trial name
- NCT02023606
- Testing
- SPN-810M
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Child Behavior Disorders
Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes
The goal of the current trial is to assess the feasibility of a newly developed prototype of a cell phone app called VillageWhere.
- Trial name
- VillageWhere (NCT02320903)
- Testing
- VillageWhere App
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD)
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as…
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Trial name
- NCT07220330
- Testing
- QbMobile
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Qbtech AB
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
- Trial name
- NCT02795637
- Testing
- dasotraline
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With ADHD
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00150579
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
- Volunteers
- 240 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
The purpose of this study is to evaluate the dose strength equivalence of to-be-marketed (TBM) centanafadine (CTN) once daily (QD) extended release (XR) when administered as 2 capsules of 164.4 milligrams (mg) or as a single…
- Trial name
- NCT07253441
- Testing
- CTN XR (TBM), CTN SR, CTN XR (Clin)
- Where
- 2 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioural…
- Trial name
- NCT00304681
- Testing
- OROS*-Methylphenidate
- Volunteers
- 147 people
- Sponsor
- Janssen-Ortho Inc., Canada